Oli is a senior associate in our Cambridge office and is part of the Corporate Technology team.
Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.
We advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press releasevon Ross McNaughton und Oli Denne
Advising Nuclera on its US$75 million series C financing
von mehreren Autoren
Advising Healx on its $47 million Series C funding
von mehreren Autoren
von Dr. Axel Frhr. von dem Bussche, LL.M. (L.S.E.), CIPP/E und Prof. Dr. Michael Johannes Pils
von mehreren Autoren
von mehreren Autoren
von Jason Rawkins und Simon Jupp
von mehreren Autoren
von mehreren Autoren
von mehreren Autoren
von Jason Rawkins und Simon Jupp
von mehreren Autoren